Management of Penetrating Aortic Ulcer (PAU) with Associated Intramural Hematoma (IMH)
Diagnosis and Risk Stratification
- The European Society of Cardiology recommends that PAU in the ascending aorta with associated IMH has a 33-75% rupture risk, necessitating urgent surgical repair 1, 2
- The presence of IMH with PAU represents a high-risk feature that may be a precursor to aneurysm rupture, according to the European Heart Journal 3, 1, 2
- PAU associated with IMH is explicitly listed as a high-risk feature warranting consideration for intervention even in the absence of other complications, as stated by the European Society of Cardiology 3, 4
Initial Medical Management
- The European Society of Cardiology recommends immediate aggressive medical therapy for all patients with PAU-IMH, with hemodynamic targets including heart rate ≤60 beats per minute and systolic blood pressure <120 mmHg 3, 1, 2, 4
- The American College of Cardiology suggests using intravenous beta-blockers as first-line therapy to achieve a heart rate ≤60 beats per minute 4
- The European Society of Cardiology advises against initiating vasodilators before achieving heart rate control, as reflex tachycardia will increase aortic wall stress 4
Diagnostic Approach
- Contrast-enhanced CT is the diagnostic technique of choice with 96% sensitivity for detecting IMH associated with PAU, according to the Journal of the American College of Radiology and the European Society of Cardiology 6, 4, 5
- The classic PAU appearance is a mushroom-shaped protrusion with overhanging edges penetrating through the internal elastic lamina, as described by the European Society of Cardiology 4
Indications for TEVAR in Type B PAU-IMH
- The European Society of Cardiology recommends TEVAR for complicated Type B PAU-IMH, defined by recurrent or persistent pain despite medical therapy, expansion of the IMH on serial imaging, periaortic hematoma, intimal disruption, or presence of high-risk imaging features 3, 1, 2
- For uncomplicated Type B PAU-IMH, TEVAR should be considered (Class IIa recommendation) given the inherently high-risk nature of this combination, as stated by the European Society of Cardiology 3, 1
Surveillance Strategy
- The European Society of Cardiology recommends repeat imaging (CT or MRI) at 1 month after diagnosis, then at 3, 6, and 12 months, and annually thereafter if stable, for patients managed medically (uncomplicated Type B PAU-IMH without intervention) 3, 4, 5
Long-Term Medical Management
- The European Society of Cardiology advises indefinite medical therapy for all PAU-IMH patients, including strict blood pressure control (systolic <120 mmHg) indefinitely, LDL-C reduction by ≥50% with goal <55 mg/dL using moderate-to-high intensity statins, and low-dose aspirin 75-162 mg daily to reduce cardiovascular events 4